© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Voriconazole didn’t always have a place in the toolkit of clinicians. In the late 1990s, researchers sought a medicine capable of treating life-threatening fungal infections in those whose immune defenses ran low, often from cancer treatment or HIV. Scientists over at Pfizer built on a framework set by fluconazole, using improved side chains and substitutions to boost efficacy against Aspergillus and other tough fungi. Approval from authorities like the FDA in 2002 meant people fighting invasive aspergillosis, who had few remaining options, could receive real help. This history reminds us that every effective therapy often carries a story of trial, error, and persistence stitched together by the efforts of biochemists, doctors, and families with someone at risk.
Voriconazole stands as a triazole antifungal available in both intravenous and oral forms. Once absorbed, the medicine antagonizes fungal pathogens by inhibiting the enzyme 14-alpha-sterol demethylase—critical for making ergosterol, a vital component of fungal cell membranes. Removing ergosterol from the equation stunts cell growth and triggers death in susceptible species. Healthcare professionals rely on the flexibility of dosing and delivery, switching between tablet, suspension, and IV infusion so hospitalized and ambulatory patients have the best shot at recovery. Products reach end users labeled as Vfend in global markets, although generic equivalents now provide broader access.
Voriconazole appears as a white to off-white crystalline powder. Its chemical formula—C16H14F3N5O—captures a structure featuring a fluorinated phenyl group and a triazole ring, fundamental to its antifungal behavior. Melting points hover near 127°C, solubility in water remains poor, but organic solvents like DMSO and methanol help formulate suitable preparations. Crystalline polymorphs remain tightly quality-controlled during manufacturing, as impurity profiles and particle size influence both potency and stability.
Manufacturers package voriconazole in vials for IV, bottles for oral solutions, and tablets in multiple strengths. Each container must clearly state concentration, expiration, recommended storage (typically below 30°C), batch number, and full excipient listing. Regulatory standards require tight limits on residual solvents, heavy metals, and microbial contamination, backed by analytical certificates released only after rigorous testing. Documentation includes clear instructions that highlight interaction risks, food effects on absorption, and warnings for off-label use. Pharmacies and hospitals rely on standardization here; any slip can affect patient outcomes and legal compliance.
Chemical synthesis of voriconazole starts from tricyclic raw materials. Stepwise reactions add methyl and fluorine functional groups, followed by coupling with a triazole intermediate. Each reaction stage demands purification techniques—crystallization, column chromatography, and vacuum drying. Yield optimization often focuses on solvent choices and reaction temperature. Waste streams and byproducts undergo neutralization and disposal consistent with environmental regulations. Integration of in-process controls, alongside batch analytics, helps prevent unwanted stereoisomers and boosts reproducibility between lots. Production must remain adaptable so upscaling doesn’t degrade chemical purity or cut corners in environmental safeguards.
Voriconazole’s triazole ring enables specific enzyme targeting yet allows chemists room for further derivatization. Modifications may swap out small groups on the aromatic ring, aiming to tweak tissue distribution or minimize side branches that set off toxicity. Researchers probe active-site analogs looking for compounds with broader antifungal ranges or less cross-reactivity with human cytochrome P450s. The chemistry also opens doors to prodrug approaches, favoring metabolic releases in target tissues—a strategy that may moderate unwanted side effects in future generations.
In the marketplace, voriconazole most commonly appears under brand names like Vfend, but generic versions proliferate as patent barriers dissolve. International reference texts also label it as UK-109,496, referencing development code names. Pharmacopeias assign unique registration numbers to minimize prescription errors across regions with language differences or alternative trade designations. Such multiplicity in names challenges logistics, forcing clarity in supply chains and digital health records to prevent duplication or confusion in clinical settings.
Clinical safety emerges as a blend of engineering, education, and surveillance. Patients and staff get guidance to guard against photosensitivity, liver toxicity, and drug interactions—especially with immunosuppressants, warfarin, and some statins. Hospitals keep emergency protocols for anaphylaxis or cardiac arrhythmias, as QT prolongation has cropped up during infusions. Regular liver function tests back up acute safety, with dose adjustments tailored for age, weight, or genetic differences in liver enzymes. On the pharmacy side, controlled storage and careful dissolution for IV use keep potency from drifting. Waste from opened vials or expired drugs needs incineration or chemical destruction to avoid accidental harm or misdirection into water supplies. Quality assurance teams must train staff to recognize warning signs of contamination or overdose, as lapses in both storage and handling undermine published safety data attained in clinical trials.
Voriconazole rose to prominence as a treatment for invasive aspergillosis, especially in patients with depleted immune defenses. Doctors also use it for scedosporiosis and fusariosis, infections notorious for sidestepping earlier treatments. Bone marrow and organ transplant recipients stand among those most in need. Pediatric doctors have fought for access to properly dosed suspensions, noting that some children cannot swallow tablets or tolerate ethanol-laden oral solutions. While frontline therapies against Candida albicans often rely on alternative drugs, voriconazole finds a place for rare or drug-resistant species. Veterinary specialists sometimes prescribe it for fungal infections in horses and small animals, broadening its reach outside human medicine.
Pharmaceutical development teams and academic groups continue to scrutinize voriconazole’s metabolism and molecular targets. Studies draw on genetic screening, trying to tie CYP2C19 allele status with variations in drug levels and responses. Research also nudges at novel delivery techniques—like nanoparticle carriers or pegylation—to stretch half-life and reduce injection site irritation. Clinical trials evaluate voriconazole in other disease areas, such as chronic pulmonary aspergillosis and certain endemic mycoses. Global collaborations map resistance mechanisms among environmental fungi, striving to anticipate emerging threats before widespread clinical failures. R&D expenditures reflect not just the effort to stretch patent life, but the sheer unpredictability of fungal pathogens in new and changing patient groups.
Toxicological work uncovers both predictable and rare hazards with voriconazole use. Off-target liver enzyme elevations, hallucinations, and visual disturbances dot the adverse event landscape. The phototoxic potential emerged only as sun-exposed patients developed skin changes akin to early aging or, in rare cases, skin cancers after prolonged use. Dose-finding trials in children outline a fine margin of error, putting the onus on therapeutic drug monitoring to avoid underdosing or toxic peaks. Animal studies and postmarketing reports keep surfacing concerning cross-reactions or allergic flares with triazole exposure, prompting regulatory agencies to update prescribing guidelines and push for risk management plans.
Tomorrow’s advances hinge on crystal-clear understanding and sharper delivery. Orally stable formulations, tailored for diverse patient needs, will likely cut down on hospitalization. Artificial intelligence-driven diagnostic tools may link fungal genetics with drug response, encouraging doctors to personalize voriconazole dosing. Research into companion diagnostics holds promise for nipping serious liver reactions in the bud, as well as extending drug use to species now marginally susceptible. Global warming and agricultural use of triazole fungicides keep pushing resistance, so both surveillance and next-generation chemistry remain on the strategic agenda for pharma and public health agencies. A deeper pool of real-world data—pulled from both cancer centers and rural hospitals—can sharpen risk-benefit calculus, ensuring that an old solution stays relevant for modern-day threats. In my experience, such medicines endure not by standing still but by adapting through science, vigilance, and honest dialogue between regulators, industry, and those whose lives change thanks to a pill or an infusion.
Voriconazole plays a crucial role in hospitals where people face life-threatening fungal infections. Unlike a typical cold, these infections often strike folks whose immune systems are wiped out from chemo, organ transplant, or uncontrolled HIV. Those with healthy immune responses barely notice when mold spores float by on a gust of wind. But that same spore can bring chaos to a patient recovering from leukemia. Fungi like Aspergillus and some oddball yeasts exploit any open door the body leaves, and Voriconazole steps up to close that door.
I remember when a friend working in an oncology ward told me about patients with lung shadows—a sign of invasive aspergillosis. Standard antibiotics can’t help, because we’re not dealing with bacteria. Oral options like fluconazole barely make a dent in aggressive mold infections. Doctors trust Voriconazole for its ability to target tough-to-kill invaders. It’s not for every cough or sniffle, but when immune defenses collapse, this drug becomes the lifeline.
Voriconazole works against infections that others just can’t touch. Aspergillus stands out, causing deadly lung and sinus infections. In some hospitals, rare molds or yeast infections in the bloodstream (known as candidemia, especially those resistant to fluconazole) need a heavy hitter. The FDA approved Voriconazole because it can clear these pathogens faster than older antifungals, improving survival rates in high-risk populations. Specialty care teams lean on it whenever odds look bleak.
Using Voriconazole brings its own set of problems. Not every patient handles it the same. Side effects range from vision changes and hallucinations to more serious issues like liver damage. It’s vital to keep an eye on liver enzymes and make dose adjustments for kids, the elderly, or anyone with kidney problems. The drug interacts with everyday medications—some blood thinners, heart rhythm pills, and anti-HIV drugs clash with it—so prescription should only come from a doctor skilled in complex cases.
Fungi adapt fast. Overuse of powerful antifungals helps tough strains survive. These can spread in hospitals, especially in parts of the world that see broad antifungal use. In my city during COVID surges, cases of ‘black fungus’ (mucormycosis) soared among vulnerable patients, and the shortages of effective antifungals (Voriconazole included) brought tragedy to many. Stewardship must stay a priority. Giving Voriconazole only when proven necessary supports the tool’s power for years to come.
Most don’t hear much about antifungals unless their family goes through a bone marrow transplant or a long ICU stay. Yet fungal threats—in hospitals, after natural disasters, and even on construction sites—keep finding new ways to break through human defenses. Climate change, urbanization, and unchecked medication use keep raising infection risks. Beyond clever drug design, we need more public health action: infection prevention in hospitals, faster diagnostics, and education about hygiene for those whose immunity is at risk.
Voriconazole isn’t just another drug on the hospital shelf. It often marks the line between hope and heartbreak for patients knocked down by dangerous molds and yeasts. By using it right and protecting its power, care teams give some of the sickest people their best shot at recovery.
Voriconazole treats serious fungal infections. We see it come up alongside bone marrow transplants, chemotherapy for leukemia, or after long ICU stays. Most people taking this drug already have some pretty major stuff going on. I remember talking with a patient who got prescribed voriconazole after a tough bout of pneumonia. She wanted the facts, not medical jargon, so let’s keep things clear and straight from people’s experiences.
Your stomach won’t always welcome voriconazole. About one out of every four to five people taking it ends up with stomach pain, feeling sick, sometimes even vomiting. It’s tough watching folks have to choose between fighting off a dangerous fungus and managing these daily challenges. In my experience, a lighter meal before taking a dose makes things a touch easier. Stomach issues don’t always mean you need to stop, but they definitely can wear you down over time.
A strange thing happens to about a third of patients: vision seems different. People see bright lights as much more intense, notice colors look oddly bright, or have blurry vision out of nowhere. These problems hit hard in the first week on the medicine. For most, it fades in a few weeks. But I’ve listened to folks describe how unsettling it feels to notice halos around streetlights or to feel unsafe driving. Telling your doctor right away helps—they might adjust other treatments or timing to make these symptoms less scary.
Red, itchy skin shows up more often than people expect. Almost one in five patients get a rash or sensitive skin. Some rashes clear up fast, but a few can turn serious. For patients with lighter skin, sunburn comes fast. Doctors recommend sunscreen and hats even on cloudy days. The more someone relies on sun exposure for daily routines, the harder this lifestyle shift feels.
Bloodwork matters. I’ve lost count of how many people walked in feeling fine but saw their routine blood tests flag a liver enzyme problem after starting voriconazole. The medicine can make the liver work overtime. These changes don’t cause pain, but yellowing eyes or skin should never be ignored. Staying in touch with your care team and reporting anything unusual, even if it’s just some yellowing to the whites of the eyes, can catch problems early.
Most people taking voriconazole already juggle lots of medicines or treatments. The best advice I’ve seen work: don’t hide new symptoms hoping they just go away. Dermatologists for skin issues and ophthalmologists for vision changes add real support. Pharmacists help, too—they can track drug interactions, remind about sun safety, or help adjust your schedule to make stomach symptoms less harsh. And don’t underestimate the value of talking through side effects with people who have been through it. Shared experience makes the burden feel lighter, and sometimes that’s as important as the medicine itself.
Voriconazole has become a mainstay for treating invasive fungal infections like aspergillosis and some rare molds. Having worked with patients battling these dangerous infections, I've seen what proper use can achieve—and what can go wrong when dosing goes off track. This isn’t a casual medication you grab over-the-counter. People trust it when other treatments fail, but taking it right takes attention to detail.
Doctors usually start with a loading dose if the infection calls for quick action. This isn’t a step to overlook; the goal is to reach helpful levels in the blood as fast as possible. Tablets and oral suspension dominate for outpatient care. Hospitals rely on IV versions when people can’t swallow or need tighter control early in treatment. Neither option works better on an empty stomach. Fatty or heavy foods keep your body from absorbing enough medicine.
From what patients share during clinic visits, a list of pills every day can feel overwhelming. Missing a dose of voriconazole risks under-treating a tough fungal bug. The discipline becomes even tougher with twice-daily dosing, and the side effects don’t always help. Nausea, vision changes, and rashes can make people want to stop—but skipping isn’t safe. I see best outcomes in people who carve out a routine, keep water on hand, and talk about every side effect, not just the alarming ones, with their medical team.
No story about this medicine should leave out drug interactions. More than half of patients I’ve seen are surprised by how many of their drugs clash with voriconazole—think statins for cholesterol, warfarin for blood-thinners, even certain antibiotics. Add liver problems, and the stakes climb higher. Regular liver tests feel like a hassle, but they spot trouble early before it snowballs.
People with poor liver function, kids, and older adults process voriconazole differently. Doses may shrink or stretch. Even the link between sunlight and skin cancer risk gets more real on voriconazole. The medicine raises the odds of sunburn and skin changes. I tell everyone: pull out that high-SPF sunscreen and keep it in your bag—to avoid a surprise burn even after a short walk outdoors.
Few drugs push doctors and patients to check levels in the blood like voriconazole. Getting the dose just right takes blood draws, conversations, and a willingness to make changes if someone lands too high or too low. This doesn't just save lives—it prevents avoidable side effects and makes sure every dose packs the right punch. Reminders on the phone, pill boxes, and family support improve consistency in practice.
In clinics and hospitals, it takes teamwork from pharmacists, providers, and the people taking the drug. Check interactions every time a new prescription shows up. Stick to the dosing routine. Pay attention to mood, vision, and skin. Support goes a long way—there’s nothing abstract about needing safety when health is already on the line. Every real-life success with voriconazole comes down to knowledge, vigilance, and a willingness to speak up when things don't feel right.
Voriconazole fights off serious fungal infections. Doctors turn to it because common bugs like Aspergillus and Candida can turn deadly fast, especially for folks with weakened immune systems. Yet, voriconazole doesn't play nice with many other medicines. Having seen how easily drug interactions can sneak up, this always deserves a close look. Patients sometimes juggle a dozen pills a day. Swapping one for another or forgetting which ones matter most leads to trouble you rarely see coming.
Voriconazole goes through the liver's metabolic highway called cytochrome P450 enzymes, mostly CYP2C19, CYP2C9, and CYP3A4. Drugs using these same enzymes sometimes compete, block each other, or get turbo-charged by voriconazole, raising the risk of side effects or dropping the levels until the medicine barely works.
Statins—used for cholesterol—can build up, causing muscle pain or damage. Warfarin—an old blood thinner—gets unpredictable, as blood can thin too much and trigger dangerous bleeding. Certain antidepressants (like sertraline or amitriptyline) can spike in the blood, turning minor side effects into big problems. Anyone taking these combinations needs extra lab checks and sometimes dose changes.
Heart rhythm drugs deserve special mention. Quinidine, amiodarone, and sotalol all run the risk of causing irregular beats when mixed with voriconazole. The combination can even set off Torsades de Pointes, a serious, sometimes fatal, heart rhythm. Medications lowering potassium levels, like some diuretics, multiply the danger.
Seizure medications like phenytoin and carbamazepine often drop voriconazole's effectiveness so low the infection keeps on growing. Doctors who miss this interaction might be left wondering why treatment fails, when the answer hides in another pill bottle. Birth control pills, used by millions, can lose their punch. Patients relying on them for pregnancy prevention need backup.
Over-the-counter drugs aren’t innocent here—I’ve seen omeprazole, a common reflux treatment, tangle with voriconazole, sometimes pushing drug levels over safe limits. Herbal supplements like St. John’s Wort can empty the blood of voriconazole faster than the fungus can be killed, leading to more failed courses of therapy.
Clear communication often makes the difference. Pharmacists routinely catch these issues, but the system breaks down if folks don’t list supplements or changes. I’ve worked with teams that make a point of calling patients in the first days after starting voriconazole, double-checking every new prescription. Lab testing can reveal problems days before patients feel symptoms, so regular bloodwork isn’t just red tape.
Educational sessions can help, too. Every patient on voriconazole deserves straight talk about possible dangers. Public health resources highlighting high-risk combos—published by university hospitals and major clinics—give both doctors and patients reliable checklists.
Electronic health records with real-time drug interaction alerts help spot risky combinations. Still, no software beats a thoughtful provider who reviews a patient’s entire medication list at every visit. Patients need benches of support—doctors, pharmacists, nurses—working together to keep treatments safe and effective. Monitoring isn’t just a box to check; it’s a real way to stop tragedies before they start.
Voriconazole helps treat serious fungal infections, especially for folks whose immune systems can’t keep up. Doctors often use it for people with conditions like leukemia or after organ transplants. But voriconazole can cause big trouble for some patients. I remember, back during my pharmacy rotations, how carefully the team screened for medication conflicts, because with voriconazole, a single mistake can send someone to the ICU.
Some drugs don’t mix with voriconazole. Carbamazepine or rifampin, for example, mess with how voriconazole breaks down in the body. Pretty quickly, the drug disappears before it has a chance to work, or toxic levels stick around—neither situation works out well. Health Canada and the FDA both highlight this interaction in their warnings. Patients on certain statins, like simvastatin or lovastatin, risk muscle breakdown and kidney issues if they mix these with voriconazole.
People with cirrhosis or chronic liver problems run into higher risks with voriconazole. The liver breaks down the drug, so impaired liver function lets the medication build up, raising the odds of side effects like hallucinations or vision changes. My colleague once cared for a patient with late-stage liver disease who landed back in the hospital after a single dose, confused and nearly blind from drug toxicity.
Kidney dialysis patients also need extra caution. The intravenous form of voriconazole contains a solubilizer—sulfobutylether beta-cyclodextrin sodium. This additive can stick around in folks with poor kidney function, reaching unsafe levels and causing more problems than it solves.
Allergies to azoles—like fluconazole or itraconazole—signal trouble with voriconazole. Some people break out in rashes or worse, trigger full-blown anaphylaxis. Someone allergic to corn products must also avoid the IV voriconazole solution, since it’s made using corn-derived ingredients. Over the years, people have ended up in the ER because no one caught their corn allergy ahead of time.
Voriconazole dosing in children gets tricky. The way kids process drugs shifts with each growth spurt, so getting the balance right isn’t easy. Medication errors can flip a routine dose into a crisis. Elderly people, especially those over 65, hold onto voriconazole longer than younger adults—meaning they’re more likely to face tremors, confusion, or heart rhythm issues.
Some folks, because of their genes, can't clear voriconazole at a normal pace. Pharmacogenetic testing can spot these people, which helps clinicians adjust or pick a safer option. For those with heart problems—specifically long QT syndrome or irregular heartbeats—voriconazole increases chances for dangerous arrhythmias. This isn’t just theory, either: stories of sudden cardiac death connected to azole antifungals have turned up for decades.
Doctors and pharmacists must check medication lists, look for allergies, and run liver and kidney tests before trusting someone with voriconazole. Patients need clear communication, including reasons to call for help if things go sideways. With so many other antifungals out there, choosing the right one always means looking at the whole person, not just the infection.
| Names | |
| Preferred IUPAC name | (2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol |
| Other names |
Vfend UK-109496 voriconazolum R-7282 VCZ |
| Pronunciation | /ˌvɔːrɪˈkɒnəzoʊl/ |
| Identifiers | |
| CAS Number | 137234-62-9 |
| Beilstein Reference | 2311250 |
| ChEBI | CHEBI:77971 |
| ChEMBL | CHEMBL: CHEMBL1250 |
| ChemSpider | 5030 |
| DrugBank | DB00582 |
| ECHA InfoCard | 03bb7080-0000-4e6e-9e23-a9d2b843f44c |
| EC Number | 2.3.1.169 |
| Gmelin Reference | 755016 |
| KEGG | D04542 |
| MeSH | D017666 |
| PubChem CID | 57370 |
| RTECS number | YV5800000 |
| UNII | 4N848TJP6C |
| UN number | UN3077 |
| CompTox Dashboard (EPA) | DTXSID4020708 |
| Properties | |
| Chemical formula | C16H14F3N5O |
| Molar mass | 349.3 g/mol |
| Appearance | A white or almost white powder |
| Odor | Odorless |
| Density | 1.45 g/cm3 |
| Solubility in water | 0.71 mg/mL |
| log P | 1.817 |
| Vapor pressure | 5.2E-14 mmHg |
| Acidity (pKa) | 9.1 |
| Basicity (pKb) | 2.65 |
| Magnetic susceptibility (χ) | -6.2×10^-6 cm³/mol |
| Refractive index (nD) | 1.521 |
| Dipole moment | 3.1464 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 576.2 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -60.7 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -6636 kJ/mol |
| Pharmacology | |
| ATC code | J02AC03 |
| Hazards | |
| Main hazards | Causes serious eye damage. May cause an allergic skin reaction. |
| GHS labelling | GHS05, GHS07, GHS08 |
| Pictograms | Voriconazole|Hepatotoxicity|Visual disturbances|Phototoxicity|Teratogenicity|QT prolongation |
| Signal word | Danger |
| Hazard statements | H302, H319 |
| Precautionary statements | P201, P202, P261, P264, P270, P272, P273, P280, P302+P352, P304+P340, P305+P351+P338, P308+P313, P333+P313, P337+P313, P362+P364, P405, P501 |
| NFPA 704 (fire diamond) | 1-2-0 Health:1 Flammability:2 Instability:0 |
| Flash point | 81.7 °C |
| Lethal dose or concentration | LD50 Oral Rat: 280 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Voriconazole: 200 mg/kg (rat, oral) |
| NIOSH | VTB42740 |
| PEL (Permissible) | 0.1 mg/m³ |
| REL (Recommended) | 200 mg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Fluconazole Itraconazole Ketoconazole Posaconazole Ravuconazole Efinaconazole |
